2021
-
Feb.
Receives KNDA (Korea New Drug Award)
-
Jan.
Establishes subsidiary, mCureX Therapeutics, Inc.
- Home
- About OliX
About OliX
History
2020
-
Dec.
Certified as Family–friendly and Innovative pharmaceutical company
-
Oct.
[OLX301A · OLX301D] Expanded Out-Licensing Agreement
with Théa (Worldwide excl. Asia- Pacific)[OLX101A] IND Phase 2 study permitted (US)
-
Jun.
R&D(GalNAc-siRNA) Supply contract with
global pharmaceutical company -
Mar.
The GalNAc Technology from AM Chemicals is instituted
2019
-
Nov.
[OLX101A] Phase 1 clinical trial for OLX10010
(candidate substance for the treatment
of hypertrophic scarring) is completed in the UK -
Apr.
[OLX201A] Candidate substance for the treatment
of Idiopathic Pulmonary Fibrosis is patented in the US -
Mar.
[OLX301A] Out-Licensing Agreement with Théa Open Innovation
(EU, MEA, Africa) -
Feb.
[OLX103] Candidate substance for the treatment
of Atopic Dermatitis is patented in the USOliX San Diego R&D Lab is established
2018
-
Nov.
Compound for increasing siRNA and RNA interference
effects is patented in Korea[OLX101A] Candidate substance for the treatment
of hypertrophic scarring is patented in Europe[OLX101A] Phase 2 clinical trial is approved in Korea
for candidate substance for the treatment of hypertrophic scarring -
Oct.
Phase 1 study of OLX10010, a potential treatment
for hypertrophic scar using a self-delivering RNAi compound,
is selected as a KOREA Drug Development
Fund project OliX US Inc. is established -
Jul.
[OLX301A] Candidate substance for the treatment
for age-related macular degeneration is patented in the USOliX gets listed on the KOSDAQ
-
May.
[OLX101A] CTA approves phase 1 clinical trial
for the treatment of hypertrophic scarring
in the UK (MHRtrial for OLX10010 (candidate A)[OLX101A] Phase 1 clinical trial
for OLX10010 (candidate substance for the treatment of
hypertrophic scarring) is completed in Korea
2017
-
Oct.
OliX passes the technology evaluation (A, A) for IPO
-
Jun.
The Sr. VP receives the KFDA Award
-
May.
Asymmetric lasiRNA platform is patented in the US
-
Feb.
The Nucleic Acid Eye Center is opened
-
Jan.
OliX moves its company to Suwon
[OLX101A] Phase 1 clinical trial is approved
in Korea forcandidate substance for
the treatment of hypertrophic scarring
2016
-
Dec.
The CEO receives the Minister of Health & Welfare Award
-
Jul.
[OLX101A] Hypertrophic scarring therapeutics data
in Journal of Investigative Dermatology is published -
Apr.
Series B funding is completed
-
Mar.
[OLX102] (a skin whitening substance) gets listed on ICID
2015
-
Jul.
OliX gets certified as Technology Innovative Small
to Medium Enterprise (INNO-BIZ) -
Jun.
Hugel Inc. makes a strategic investment in OliX
-
Apr.
'Development of RNA interference based atopic dermatitis
treatment' is selected as a Technology Development Support Project
(KOREA Small and Medium Business Administration)
2014
-
Nov.
'Pre-clinical and clinical study of anti-scarring therapeutics BMT101
self-delivering RNAi molecule.' is selected
as a KOREA Drug Development Fund project -
Oct.
The company name is changed to OliX, Inc.
-
Sep.
'Therapeutics development for Idiopathic Pulmonary
Fibrosis using BMT101 a pre-validated oligonucleotide drug
inhibiting fibrosis' is selected as a Korea-Singapore
R&D project (Ministry of Health and Welfare) -
Aug.
Series A funding is completed
2013
-
Nov.
[OLX101A] OliX makes a Collaboration and License
Agreement with Hugel Inc. for the treatment of hypertrophic scarring -
May.
A patent application for cp-asiRNA platform is filed
-
Feb.
Angel investment is raised
2012
-
Nov.
OliX moves to Gasan Digital Complex
-
May.
Patent application for cp-asiRNA platform is filed
2011
-
Dec.
cp-asiRNA platform development is initiated
-
Oct.
Company affiliated research center is certified
-
Jun.
An exclusive license for asymmetric lasiRNA is obtained
2010
-
Sep.
OliX gets certified as a venture company (Kibo Technology Fund)
-
Mar.
An exclusive license for asymmetric siRNA is obtained
-
Feb.
BMT, Inc. is established
LOGO DESIGN
-
2010.02 ~ 2012.10
-
2012.11 ~ 2014.09
-
2014.10 ~ Present